Lunit announced on the 15th that it has entered into a supply contract with GC Biopharma for its chest X-ray image analysis artificial intelligence (AI) ‘Lunit Insight CXR’ and mammography image analysis AI ‘Lunit Insight MMG.’
Under this contract, Lunit Insight AI will be utilized at the Gangnam and Gangbuk clinics of GC i-MED, which is a comprehensive health screening institution. GC i-MED is actively introducing the latest medical equipment and AI.
Lunit is set to expand its business area into the health screening market through this contract. In particular, this contract marks the first case of Lunit AI being introduced as a non-reimbursable item in the health screening environment. Previously, Lunit Insight had only been used as a non-reimbursable service in outpatient diagnosis areas, including comprehensive hospitals.
During breast screenings utilizing Lunit Insight MMG, participants will receive an ‘AI mammography image analysis report’ along with the regular health screening report. This report includes interpretation opinions and allows patients to check customized information such as methods for preventing breast cancer and instructions for follow-up examinations through a QR code.
Seo Beom-seok, CEO of Lunit, noted, “The Lunit AI technology, which has proven its performance and efficacy through adoption in global medical institutions and various clinical studies, is now reaching a significant turning point for expansion into the screening environment. In particular, this supply is significant as it represents the first application of non-reimbursable medical treatment in the screening environment, and we will take this opportunity to strengthen our foothold in the domestic market.”